Trials / Unknown
UnknownNCT06171984
Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal
Thrombophilia Assessment Under Direct Oral Anticoagulants (DOAC): Efficacy of Activated Charcoal
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Direct oral anticoagulants (DOAC) are anticoagulant molecules that act either directly on factor Xa (Apixaban, Rivaroxaban) or on factor IIa (Dabigatran). AODs interfere with most coagulation tests, especially those performed by chronometric technique. For this reason, part of the thrombophilia workup (protein S, search for lupus anticoagulants, antithrombin for patients on dabigatran) cannot be performed on DOACs at the HUS. Recent studies have highlighted the effectiveness of activated charcoal to adsorb DOACs in order to perform certain hemostasis tests.
Conditions
Timeline
- Start date
- 2022-07-19
- Primary completion
- 2024-01-01
- Completion
- 2024-01-19
- First posted
- 2023-12-15
- Last updated
- 2023-12-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06171984. Inclusion in this directory is not an endorsement.